Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 7Dermatologic 6Other hematologic neoplasm 5Lymphoid 5Genitourinary 5Myeloid 4Breast 4Sarcoma 3Plasma cell 3Gastrointestinal 2Thoracic 1Gynecologic 1Classical hematology 1

Conditions

Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Colony-Stimulating Factors × Gynecologic × Clear all
NCT00436254 2025-04-06

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

University of Washington

Phase 1 Completed
66 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡